Major Estimate Revision • May 14
Consensus EPS estimates increase by 29%, revenue downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from ₩398.8m to ₩385.7m. EPS estimate rose from ₩6,790 to ₩8,726. Net income forecast to grow 373% next year vs 56% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩73,600 unchanged from last update. Share price rose 5.3% to ₩53,800 over the past week. Announcement • May 09
Dentium CO., LTD to Report Q1, 2026 Results on May 12, 2026 Dentium CO., LTD announced that they will report Q1, 2026 results on May 12, 2026 New Risk • Apr 03
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 50% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.7% net profit margin). Announcement • Mar 25
Dentium CO., LTD (KOSE:A145720) announces an Equity Buyback. Dentium CO., LTD (KOSE:A145720) announces a share repurchase program. Under the program, the company will repurchase up to KRW 60,000 million worth of its shares, pursuant to a contract with NH Investment & Securities. The purpose of the program is enhancement of shareholder value . The program will expire on March 31, 2027. As of March 24,2026, the company had 49,950 shares in treasury within scope available for dividend and had no shares in treasury under other capacities. Price Target Changed • Mar 13
Price target increased by 8.2% to ₩73,600 Up from ₩68,000, the current price target is an average from 5 analysts. New target price is 39% above last closing price of ₩52,900. Stock is down 15% over the past year. The company is forecast to post earnings per share of ₩3,601 for next year compared to ₩8,431 last year. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₩54,400, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 54% over the past three years. Major Estimate Revision • Mar 08
Consensus EPS estimates increase by 24% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩384.9m to ₩408.1m. EPS estimate increased from ₩5,755 to ₩7,143 per share. Net income forecast to grow 32% next year vs 38% growth forecast for Medical Equipment industry in South Korea. Consensus price target up from ₩70,000 to ₩73,000. Share price was steady at ₩50,200 over the past week. Announcement • Mar 06
Dentium CO., LTD, Annual General Meeting, Mar 31, 2026 Dentium CO., LTD, Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 140, gwanggyojungang-ro, yeongtong-gu, gyeonggi-do, suwon South Korea Announcement • Mar 05
Dentium CO., LTD announces Annual dividend Dentium CO., LTD announced Annual dividend of KRW 600.0000 per share, ex-date on March 20, 2026 and record date on March 23, 2026. Price Target Changed • Feb 06
Price target decreased by 9.1% to ₩70,000 Down from ₩77,000, the current price target is an average from 5 analysts. New target price is 45% above last closing price of ₩48,200. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₩3,601 for next year compared to ₩8,431 last year. Announcement • Dec 12
Dentium CO., LTD(KOSE:A145720) dropped from KOSPI 200 Index Dentium CO., LTD has been dropped from the KOSPI 200 Index. Price Target Changed • Nov 15
Price target decreased by 13% to ₩77,000 Down from ₩89,000, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩55,100. Stock is down 1.1% over the past year. The company is forecast to post earnings per share of ₩3,775 for next year compared to ₩8,431 last year. Major Estimate Revision • Nov 13
Consensus revenue estimates decrease by 12% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩366.3m to ₩324.1m. EPS estimate unchanged from ₩6,086 per share at last update. Medical Equipment industry in South Korea expected to see average net income growth of 42% next year. Consensus price target of ₩89,000 unchanged from last update. Share price was steady at ₩57,100 over the past week. New Risk • Sep 26
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.1% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (14% net profit margin). Major Estimate Revision • Aug 20
Consensus revenue estimates decrease by 12%, EPS upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩407.9m to ₩360.0m. EPS estimate increased from ₩6,216 to ₩6,604 per share. Net income forecast to shrink 9.4% next year vs 38% growth forecast for Medical Equipment industry in South Korea . Consensus price target of ₩89,000 unchanged from last update. Share price fell 2.6% to ₩59,900 over the past week. Major Estimate Revision • Jun 05
Consensus EPS estimates fall by 12% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩7,757 to ₩6,861 per share. Revenue forecast steady at ₩417.8m. Net income forecast to grow 8.1% next year vs 51% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩95,000 to ₩89,000. Share price rose 4.5% to ₩64,800 over the past week. Valuation Update With 7 Day Price Move • May 12
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩61,100, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩32,655 per share. New Risk • May 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Major Estimate Revision • May 10
Consensus EPS estimates fall by 36% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩439.1m to ₩421.7m. EPS estimate also fell from ₩8,531 per share to ₩5,467 per share. Net income forecast to shrink 17% next year vs 26% growth forecast for Medical Equipment industry in South Korea . Consensus price target down from ₩99,000 to ₩97,000. Share price fell 11% to ₩64,800 over the past week. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩73,300, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 3.4% over the past three years. Announcement • Mar 06
Dentium CO., LTD, Annual General Meeting, Mar 31, 2025 Dentium CO., LTD, Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 145, gwanggyo-ro, yeongtong-gu, gyeonggi-do, suwon South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 16 April 2025. Payout ratio is a comfortable 4.0% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%). Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩57,900, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 4.5% over the past three years. Price Target Changed • Nov 11
Price target decreased by 9.8% to ₩121,250 Down from ₩134,375, the current price target is an average from 8 analysts. New target price is 101% above last closing price of ₩60,300. Stock is down 49% over the past year. The company is forecast to post earnings per share of ₩8,344 for next year compared to ₩11,193 last year. Price Target Changed • Oct 15
Price target decreased by 9.3% to ₩134,375 Down from ₩148,125, the current price target is an average from 8 analysts. New target price is 69% above last closing price of ₩79,600. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₩9,386 for next year compared to ₩11,193 last year. Price Target Changed • Aug 10
Price target decreased by 8.6% to ₩156,875 Down from ₩171,625, the current price target is an average from 8 analysts. New target price is 86% above last closing price of ₩84,300. Stock is down 40% over the past year. The company is forecast to post earnings per share of ₩8,729 for next year compared to ₩11,193 last year. Reported Earnings • Mar 26
Full year 2023 earnings released: EPS: ₩11,193 (vs ₩9,980 in FY 2022) Full year 2023 results: EPS: ₩11,193 (up from ₩9,980 in FY 2022). Revenue: ₩393.2b (up 11% from FY 2022). Net income: ₩96.5b (up 12% from FY 2022). Profit margin: 25% (in line with FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 29
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩144,300, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 142% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩281,948 per share. Upcoming Dividend • Dec 20
Upcoming dividend of ₩300 per share at 0.2% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 3.6% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%). Valuation Update With 7 Day Price Move • Oct 27
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩115,200, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 213% over the past three years. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩124,400, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years. Major Estimate Revision • Aug 11
Consensus EPS estimates fall by 12% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from ₩10,290 to ₩9,096 per share. Revenue forecast steady at ₩416.5m. Net income forecast to grow 24% next year vs 32% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩184,375. Share price was steady at ₩141,400 over the past week. Major Estimate Revision • Aug 10
Consensus EPS estimates fall by 10% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from ₩10,290 to ₩9,240 per share. Revenue forecast steady at ₩418.0m. Net income forecast to grow 24% next year vs 32% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩184,375. Share price rose 2.7% to ₩145,400 over the past week. Price Target Changed • May 12
Price target increased by 7.0% to ₩161,111 Up from ₩150,556, the current price target is an average from 9 analysts. New target price is 9.7% above last closing price of ₩146,800. Stock is up 109% over the past year. The company is forecast to post earnings per share of ₩9,527 for next year compared to ₩9,980 last year. Major Estimate Revision • May 12
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩428.2m to ₩417.6m. EPS estimate also fell from ₩11,233 per share to ₩9,527 per share. Net income forecast to grow 34% next year vs 33% growth forecast for Medical Equipment industry in South Korea. Consensus price target up from ₩150,556 to ₩153,889. Share price fell 6.4% to ₩146,800 over the past week. Price Target Changed • Apr 28
Price target increased by 8.8% to ₩150,556 Up from ₩138,333, the current price target is an average from 9 analysts. New target price is approximately in line with last closing price of ₩143,900. Stock is up 111% over the past year. The company is forecast to post earnings per share of ₩11,233 for next year compared to ₩9,980 last year. Price Target Changed • Apr 25
Price target increased by 8.8% to ₩150,556 Up from ₩138,333, the current price target is an average from 9 analysts. New target price is 6.0% above last closing price of ₩142,100. Stock is up 111% over the past year. The company is forecast to post earnings per share of ₩11,233 for next year compared to ₩9,980 last year. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩139,700, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 340% over the past three years. Reported Earnings • Mar 26
Full year 2022 earnings: EPS in line with expectations, revenues disappoint Full year 2022 results: EPS: ₩9,980 (up from ₩6,434 in FY 2021). Revenue: ₩355.9b (up 22% from FY 2021). Net income: ₩86.1b (up 55% from FY 2021). Profit margin: 24% (up from 19% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 54% per year, which means it is significantly lagging earnings growth. Price Target Changed • Mar 26
Price target increased by 9.1% to ₩135,000 Up from ₩123,778, the current price target is an average from 9 analysts. New target price is 15% above last closing price of ₩117,500. Stock is up 55% over the past year. The company is forecast to post earnings per share of ₩10,807 for next year compared to ₩9,980 last year. Major Estimate Revision • Mar 07
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩436.1m to ₩428.6m. EPS estimate also fell from ₩11,324 per share to ₩9,641 per share. Net income forecast to grow 17% next year vs 27% growth forecast for Medical Equipment industry in South Korea. Consensus price target up from ₩123,778 to ₩132,111. Share price rose 2.2% to ₩123,700 over the past week. Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment improved over the past week After last week's 16% share price gain to ₩110,500, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 120% over the past three years. Upcoming Dividend • Dec 21
Upcoming dividend of ₩250 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 2.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.8%). Price Target Changed • Nov 16
Price target increased to ₩121,250 Up from ₩100,000, the current price target is an average from 8 analysts. New target price is 50% above last closing price of ₩80,800. Stock is up 34% over the past year. The company is forecast to post earnings per share of ₩9,194 for next year compared to ₩6,434 last year. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improved over the past week After last week's 15% share price gain to ₩80,800, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 40% over the past three years. Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment improved over the past week After last week's 16% share price gain to ₩99,100, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 40% over the past three years. Price Target Changed • Aug 10
Price target increased to ₩112,500 Up from ₩100,000, the current price target is an average from 6 analysts. New target price is 11% above last closing price of ₩101,500. Stock is up 26% over the past year. The company is forecast to post earnings per share of ₩7,894 for next year compared to ₩6,434 last year. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩74,300, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 4.8% over the past three years. Major Estimate Revision • May 15
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from ₩362.2m to ₩347.5m. EPS estimate rose from ₩6,254 to ₩7,310. Net income forecast to grow 46% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩95,971. Share price rose 2.0% to ₩70,200 over the past week. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment improved over the past week After last week's 18% share price gain to ₩73,200, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 15% over the past three years. Major Estimate Revision • Mar 05
Consensus EPS estimates increase by 19% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩332.8m to ₩339.6m. EPS estimate increased from ₩5,405 to ₩6,430 per share. Net income forecast to grow 35% next year vs 32% growth forecast for Medical Equipment industry in South Korea. Consensus price target up from ₩90,543 to ₩94,543. Share price rose 32% to ₩75,600 over the past week. Upcoming Dividend • Dec 22
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 15 April 2022. Payout ratio is a comfortable 3.6% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment improved over the past week After last week's 19% share price gain to ₩64,500, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total loss to shareholders of 2.1% over the past three years. Valuation Update With 7 Day Price Move • Aug 12
Investor sentiment improved over the past week After last week's 20% share price gain to ₩88,600, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 16x in the Medical Equipment industry in South Korea. Negligible returns to shareholders over past three years. Major Estimate Revision • Aug 12
Consensus EPS estimates increase to ₩4,278 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from ₩279.7m to ₩287.0m. EPS estimate increased from ₩3,674 to ₩4,278 per share. Net income forecast to grow 79% next year vs 42% growth forecast for Medical Equipment industry in South Korea. Consensus price target up from ₩81,750 to ₩93,200. Share price rose 17% to ₩88,600 over the past week. Price Target Changed • Aug 11
Price target increased to ₩92,250 Up from ₩80,000, the current price target is an average from 6 analysts. New target price is 15% above last closing price of ₩80,500. Stock is up 83% over the past year. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment improved over the past week After last week's 16% share price gain to ₩74,500, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Medical Equipment industry in South Korea. Total loss to shareholders of 17% over the past three years. Announcement • Mar 16
Dentium CO., LTD, Annual General Meeting, Mar 30, 2021 Dentium CO., LTD, Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time. Price Target Changed • Feb 25
Price target raised to ₩63,333 Up from ₩55,667, the current price target is an average from 4 analysts. The new target price is 5.2% above the current share price of ₩60,200. As of last close, the stock is up 37% over the past year. Is New 90 Day High Low • Jan 25
New 90-day high: ₩48,500 The company is up 26% from its price of ₩38,400 on 27 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩111,883 per share. Is New 90 Day High Low • Jan 07
New 90-day high: ₩44,350 The company is up 28% from its price of ₩34,650 on 08 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩109,784 per share. Is New 90 Day High Low • Nov 11
New 90-day high: ₩44,250 The company is up 1.0% from its price of ₩43,900 on 13 August 2020. The South Korean market is also up 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩117,168 per share. Is New 90 Day High Low • Sep 23
New 90-day low: ₩35,950 The company is down 5.0% from its price of ₩37,900 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩86,029 per share.